RESUMEN
Objective: To report two cases of vitreous cysts with discussion of their pathophysiology and management. Methods: Clinical examination with fundus photography, ultrasound and optical coherence tomography. Histopathology was performed in the first case. Results: The first case illustrates a pigmented, free-floating cyst, which was removed during a 27-gauge vitrectomy. The histopathology shows a single layer of pigmented epithelium and confirms the previously reported presence of a PAS-positive basement membrane. The second case shows a sessile, non-pigmented cyst associated with significant anisometropia. Conclusion: Primary vitreous cysts are rare and can have a wide range in their clinical aspect. This likely reflects whether they originate either from the pigment epithelium or the primary hyaloidal system. The management of vitreous cysts is mostly conservative, but pars plana vitrectomy can be used safely if the symptoms are debilitating.
RESUMEN
Purpose: To evaluate the efficacy of dexamethasone intravitreal implants (DEX implant) in patients with treatment-resistant macular edema (ME) owing to branch and central retinal vein occlusion (BRVO/CRVO), and the influence of prior vitrectomy on this treatment. Methods: Multicenter retrospective chart review was performed on 40 CRVO and 32 BRVO eyes with persistent ME despite intravitreal anti-vascular endothelial growth factor agents and/or intravitreal triamcinolone, and/or laser therapy. Each patient received ≥1 dexamethasone 700 µg implant between March 2011 and December 2015. Thirteen patients underwent prior vitrectomy. Data were collected on best-corrected visual acuity (BCVA), central macular thickness (CMT), time to relapse, and adverse events. Results: At the end of follow-up, BRVO eyes had a lesser CMT reduction from baseline compared to CRVO eyes (-122.50 ± 152.47 µm and -202.26 ± 194.09 µm, respectively). Neither BRVO nor CRVO eyes had a sustained BCVA benefit (P = 0.7041 and P = 0.7027, respectively). Vitrectomized and nonvitrectomized eyes overall had a sustained significant CMT reduction throughout the study with -192.46 ± 172.62 µm and -164.02 ± 180.36 µm, respectively, at final follow-up. Similar time to relapse of 24.4 ± 6.5 and 23.3 ± 13.5 weeks, respectively, was observed. By the end of follow-up, BCVA had only improved in vitrectomized eyes. However, multivariable regression analyses showed no significant association between vitrectomy status and CMT or BCVA change after the first and last injection. Cataract formation and ocular hypertension occurred in 25% and 17%, respectively. Conclusions: Multiple DEX implant are effective in reducing CMT in patients resistant to previous treatments and appear to be similarly effective in vitrectomized and nonvitrectomized eyes.
Asunto(s)
Implantes Absorbibles , Dexametasona , Edema Macular , Oclusión de la Vena Retiniana/complicaciones , Vitrectomía , Anciano , Bélgica , Dexametasona/administración & dosificación , Dexametasona/farmacocinética , Sistemas de Liberación de Medicamentos , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/farmacocinética , Humanos , Inyecciones Intravítreas/instrumentación , Inyecciones Intravítreas/métodos , Edema Macular/diagnóstico , Edema Macular/tratamiento farmacológico , Edema Macular/etiología , Masculino , Persona de Mediana Edad , Retina/efectos de los fármacos , Estudios Retrospectivos , Resultado del Tratamiento , Vitrectomía/efectos adversos , Vitrectomía/métodos , Cuerpo Vítreo/fisiopatología , Cuerpo Vítreo/cirugíaRESUMEN
PURPOSE: To evaluate the rate of false negative results with the Heidelberg Retina Tomograph (HRT II) in a glaucoma practice. DESIGN: Cross-sectional study. METHODS: We analyzed the HRTs taken between October 2002 and October 2003 in our glaucoma clinic, and selected the patients who had a good quality image (SD < 40 mu) with a normal Moorfield's Regression Analysis (MRA). A masked independent observer classified those patients as normal, glaucoma suspect, or glaucomatous on the basis of optic disc stereo photos (ODP) and at least 2 consecutive reliable automated perimetries. The diagnosis of glaucoma was based on a glaucomatous optic disc with a congruent, reproducible visual field defect. RESULTS: Four hundred and fifty patients who had undergone an HRT examination were analyzed. One hundred and nine patients had an HRT classified as normal on the MRA, and a good quality image. Fifteen of those 109 patients (13.7%) were classified as glaucomatous on the basis of an abnormal ODP with corresponding visual field defect. Seven (6.4%) patients were classified as glaucoma suspect. CONCLUSION: Fourteen percent of glaucoma patients with glaucoma remained undetected with the HRT II Moorfield's regression analysis as a sole means to detect glaucoma.
RESUMEN
BACKGROUND: This study compares the medium-term success rate and complications of non-penetrating deep sclerectomy (NPDS) without and with autologous scleral implant in open-angle glaucoma. METHODS: Retrospective review of 93 eyes of 93 patients with medically uncontrolled open-angle glaucoma who underwent NPDS without (n=69, group 1) or with (n=24, group 2) autologous scleral implant. RESULTS: The mean follow-up was 16 months (range 5-36) in group 1 and 15 months (range 4-28) in group 2. The mean intra-ocular pressures (IOP) pre- and postoperatively were, respectively, 23.8 and 16.1 mmHg in group 1, and 25.6 and 15.8 mmHg in group 2. The absolute success rate was 41% in group 1 and 54% in group 2. The qualitative success rate was 83% in group 1 and 75% in group 2. An IOP lower than 16 mmHg was obtained in 51% of patients in group 1 and 58% of patients in group 2. A Nd:YAG laser goniopuncture was performed in 30% of patients in group 1 and 50% of patients in group 2, and resulted in a better controlled IOP. CONCLUSIONS: NPDS without or with an autologous scleral implant is a safe procedure reducing the IOP significantly, but probably not sufficient when an IOP below 16 mmHg is required. We found no statistically significant difference between the two groups.